Ferguson Wellman Capital Management Inc. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 3.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 20,500 shares of the company’s stock after selling 822 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Eli Lilly and Company were worth $23,720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. CapWealth Advisors LLC lifted its holdings in Eli Lilly and Company by 10.4% in the third quarter. CapWealth Advisors LLC now owns 10,188 shares of the company’s stock valued at $11,788,000 after acquiring an additional 962 shares during the period. Heartwood Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 9.7% during the 3rd quarter. Heartwood Wealth Advisors LLC now owns 430 shares of the company’s stock valued at $498,000 after purchasing an additional 38 shares during the period. Violich Capital Management Inc. increased its position in shares of Eli Lilly and Company by 151.0% during the 3rd quarter. Violich Capital Management Inc. now owns 3,241 shares of the company’s stock valued at $3,750,000 after purchasing an additional 1,950 shares during the last quarter. Miller Global Investments LLC increased its position in shares of Eli Lilly and Company by 17.5% during the 3rd quarter. Miller Global Investments LLC now owns 322 shares of the company’s stock valued at $373,000 after purchasing an additional 48 shares during the last quarter. Finally, Polaris Financial Partners bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $551,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: The FDA expanded Jaypirca (pirtobrutinib) approval to first-line treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion. The decision, supported by Phase 3 BRUIN CLL-313 results, broadens Lilly’s commercial opportunity in blood cancer and strengthens its oncology portfolio. FDA Expands Eli Lilly’s Blood Cancer Drug Label in First-Line Setting
- Positive Sentiment: Lilly continues to show momentum in obesity care. Reports highlight strong patient growth and market-share gains against Novo Nordisk, while early data for next-generation treatments targeting the amylin pathway suggest potential for future combination therapies beyond Zepbound. Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
- Positive Sentiment: The company expanded its multi-year collaboration with Gate Bioscience to discover small-molecule medicines for difficult-to-drug proteins, adding longer-term pipeline potential. Lilly will also present 21 dermatology studies, including encouraging durability data for Ebglyss and research involving Taltz and Zepbound. Gate Bioscience Expands Collaboration and License Agreement with Lilly
- Neutral Sentiment: Analysts and financial coverage continue to emphasize Lilly’s strong competitive position in diabetes and obesity treatments, supported by manufacturing capacity, patents and a broad pipeline. The shares’ elevated valuation means substantial future growth may already be reflected in expectations. Eli Lilly’s Valuation Has Changed
- Negative Sentiment: Several obesity-drug developments are based on early or exploratory data, so future efficacy, safety, regulatory and commercial outcomes remain uncertain. Any setbacks could weigh more heavily on LLY because its premium valuation depends on sustained growth from this market.
Insider Buying and Selling at Eli Lilly and Company
Analyst Ratings Changes
Several brokerages recently issued reports on LLY. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research report on Friday, August 7th. Citigroup lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Cantor Fitzgerald boosted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Berenberg Bank set a $1,400.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $1,419.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,311.96.
Eli Lilly and Company Price Performance
Shares of Eli Lilly and Company stock traded up $12.64 on Monday, hitting $1,155.49. 814,937 shares of the company traded hands, compared to its average volume of 2,975,996. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65. The business has a 50-day simple moving average of $1,176.33 and a 200 day simple moving average of $1,089.48. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market capitalization of $1.09 trillion, a P/E ratio of 38.76, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.
Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
- Insiders Are Selling These 3 Stocks, Should You?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
